Default: Seminars in Cancer Biology

ISSN: 1044-579X

Journal Home

Journal Guideline

Seminars in Cancer Biology Q1 Unclaimed

Academic Press Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Cancer Biology is a journal indexed in SJR in Cancer Research with an H index of 148. It has a price of 2840 €. It has an SJR impact factor of 3,908 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,908.

Seminars in Cancer Biology focuses its scope in these topics and keywords: role, nuclear, cancer, natural, molecular, microrna, mechanismsthe, malignancy, lymphomagenesisa, inflammation, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Scopus WOS
Categories: Cancer Research (Q1)
Price

2840 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Seminars in Cancer Biology

3,908

SJR Impact factor

148

H Index

287

Total Docs (Last Year)

310

Total Docs (3 years)

47920

Total Refs

3555

Total Cites (3 years)

286

Citable Docs (3 years)

11,39

Cites/Doc (2 years)

166,97

Ref/Doc

Aims and Scope


role, nuclear, cancer, natural, molecular, microrna, mechanismsthe, malignancy, lymphomagenesisa, inflammation, oncogenesis, products, receptorpositive, relationdisruption, researchnotch, resistance, stem, t, therapy, induced, impact, human, breast, cancerinfectious, cancermicroenvironmental, causal, cell, cells, cellular, cooperation, dietary, directions, ebv, estrogen, evolving, future,



Best articles by citations

Epstein-Barr virus and gastric carcinoma

View more

Definition of tumor antigens suitable for vaccine construction

View more

Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies

View more

Chemokines in neuroectodermal development and their potential implication in cancer stem cell-driven metastasis

View more

A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead

View more

Chemokines in neuroectodermal tumour progression and metastasis

View more

Genomic stability and tumorigenesis

View more

Oncogenes and tumor angiogenesis

View more

Oncogenes as therapeutic targets

View more

Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015

View more

Oncogenic growth factor receptors: implications for signal transduction therapy

View more

Current criteria to establish human carcinogens

View more
SHOW MORE ARTICLES

Putative role of 67 kDa elastin-laminin receptor in tumor invasion

View more

Fusion oncogenes and tumor type specificity - insights from salivary gland tumors

View more

Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab

View more

Familial nasopharyngeal carcinoma

View more

Regulating the regulators or how to elicit an immune response

View more

Epigenetic and proteolytic inactivation of 14-3-3s in breast and prostate cancers

View more

Hepatitis C virus and its pathogenesis

View more

AGEs, RAGEs and s-RAGE; friend or foe for cancer

View more

Introduction and overview

View more

Where is the biology of CLL leading us?

View more

Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth

View more

Cyclin E as a prognostic and predictive marker in breast cancer

View more

Comments

No comments ... Be the first to comment!

FAQS